Edward M. Christie III
Known title: DirectorCIK: 0001428519
Associated companies
Transaction History
| EHC | ▲ Buy | Grant | 248 | $28K | 7/16/2026 | View on chart |
| EHC | ▲ Buy | Grant | 11 | $0 | 7/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 1,634 | $0 | 5/7/2026 | View on chart |
| EHC | ▲ Buy | Grant | 261 | $28K | 4/16/2026 | View on chart |
| EHC | ▲ Buy | Grant | 9 | $0 | 4/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 9 | $0 | 1/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 269 | $28K | 1/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 7 | $0 | 10/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 223 | $27K | 10/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 260 | $28K | 7/16/2025 | View on chart |
| EHC | ▲ Buy | Grant | 8 | $0 | 7/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 1,424 | $0 | 5/1/2025 | View on chart |
| EHC | ▲ Buy | Grant | 268 | $27K | 4/24/2025 | View on chart |
| EHC | ▲ Buy | Grant | 5 | $0 | 4/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 292 | $28K | 1/16/2025 | View on chart |
| EHC | ▲ Buy | Grant | 6 | $0 | 1/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 283 | $28K | 10/17/2024 | View on chart |
| EHC | ▲ Buy | Grant | 6 | $0 | 10/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 334 | $29K | 7/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 6 | $0 | 7/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 1,978 | $0 | 5/2/2024 | View on chart |
| EHC | ▲ Buy | Grant | 314 | $25K | 4/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 2 | $0 | 4/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 488 | $34K | 1/17/2024 | View on chart |
| EHC | ▲ Buy | Grant | 3 | $0 | 1/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 997 | $0 | 11/27/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.